ClinicalTrials.gg
CompletedNCT06542731Updated Oct 20, 2026

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

A Phase 1 interventional study of ONO-4578 and ONO-4538 in Non-small Cell Lung Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 13 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Jun 2021, registered Aug 2024).
Updated Oct 20, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan — 96 open to participants now, 215 under way, 102 of them phase 3. Carcinoma, Non-Small-Cell Lung · Japan.

Enrollment
355th of 418
42 · median 284
Started
2021
with 38 others
Phase 1
104 of 452
19 open now
Registered
382nd of 452
by date

Among the 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan, this one is the 355th largest by enrollment of the 418 interventional ones that give a count, is one of 39 that started in 2021, is one of 104 in phase 1, and was the 382nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

96 of the 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan, or all of them as a file.
02

Study summary

This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who were refractory to a combination therapy containing an anti-PD-(L)1 antibody and a platinum-based drug

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical stage III B/ III C with unsuitable for radical irradiation, Clinical stage IV or recurrent non-small cell lung cancer
  2. of at least 3 months
  3. Patients with performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe complication
  2. Patients with multiple primary cancers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    ONO-4578+ONO-4538+docetaxel + ramucirumab

    Drug: ONO-4578 · Drug: ONO-4538 · Drug: Docetaxel · Drug: Ramucirumab

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Nivolumab

  • Specified dose on specified days

    Also known as: Taxotere

  • Specified dose on specified days

    Also known as: Cyramza

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities(DLT)

    Time frame: 21 days

  2. Adverse event(AE)

    Time frame: Up to 28 days after the last dose

Secondary outcomes

  1. Pharmacokinetics(Plasma concentration of ONO-4578)

    Time frame: Up to 28 days after the last dose

  2. Pharmacokinetics(serum concentration of ONO-4538)

    Time frame: Up to 28 days after the last dose

  3. Overall response rate (ORR)

    Time frame: Up to 2 years

  4. Disease control rate (DCR)

    Time frame: Up to 2 years

  5. Overall survival (OS)

    Time frame: Up to 2 years

  6. Progression-free survival (PFS)

    Time frame: Up to 2 years

  7. Duration of response (DOR)

    Time frame: Up to 2 years

  8. Time to response (TTR)

    Time frame: Up to 2 years

  9. Best overall response (BOR)

    Time frame: Up to 2 years

  10. Percentage of change in the sum of tumor diameters of target lesions

    Time frame: Up to 2 years

  11. Maximum percentage of change in the sum of tumor diameters of target lesions

    Time frame: Up to 2 years

  12. Changes in tumor markers(CYFRA,CEA,SLX)

    Time frame: Up to 2 years

07

Study locations

13 sites
  • Saitama Cancer Center
    Shinden, Saitama, Japan
  • National Cancer Center Hospital
    Chuo Ku, Tokyo, Japan
  • Juntendo University Hospital
    Bunkyō City, Japan
  • Teikyo University Hospital
    Itabashi-ku, Japan
  • Japan Anti-Tuberculosis Association Fukujuji Hospital
    Kiyose-shi, Japan
  • The Cancer Institute Hospital of JFCR
    Kōtoku, Japan
  • Niigata Cancer Center Hospital
    Niigata, Japan
  • Hyogo Medical University Hospital
    Nishinomiya-shi, Japan
  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute
    Osaka, Japan
  • Kitasato University Hospital
    Sagamihara-shi, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center
    Sakai, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsuki-shi, Japan
  • Kanagawa Cancer Center
    Yokohama, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2025, 52 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 52 months is close to that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2026 → Oct 2025 and completion Dec 2026 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 7, 2024
StartActual
Jun 1, 2021
Primary completionActual
Oct 30, 2025was Sep 2026
CompletionActual
Oct 30, 2025was Dec 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (6 Japan)
  • Saitama Cancer Center · Shinden, Japan
  • Juntendo University Hospital · Bunkyō City, Japan
  • The Cancer Institute Hospital of JFCR · Kōtoku, Japan
  • Niigata Cancer Center Hospital · Niigata, Japan
  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute · Osaka, Japan
  • Kanagawa Cancer Center · Yokohama, Japan
Show 6 removed
  • Saitama Cancer Center · Ina, Japan
  • Juntendo University Hospital · Bunkyo-ku, Japan
  • The Cancer Institute Hospital of JFCR · Koto-ku, Japan
  • Niigata Cancer Center Hospital · Niigata-shi, Japan
  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute · Osaka-shi, Japan
  • Kanagawa Cancer Center · Yokohama-shi, Japan
Oct 20, 2026
Primary completion
Sep 12, 2026→Oct 30, 2025 (actual)
Oct 20, 2026
Study completion
Dec 31, 2026→Oct 30, 2025 (actual)
Oct 20, 2026
Sponsor
Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    6 sites added, 6 sites removed
    Show 6 added (6 Japan)
    • Saitama Cancer Center · Shinden, Japan
    • Juntendo University Hospital · Bunkyō City, Japan
    • The Cancer Institute Hospital of JFCR · Kōtoku, Japan
    • Niigata Cancer Center Hospital · Niigata, Japan
    • Osaka Prefectural Hospital Organization Osaka International Cancer Institute · Osaka, Japan
    • Kanagawa Cancer Center · Yokohama, Japan
    Show 6 removed
    • Saitama Cancer Center · Ina, Japan
    • Juntendo University Hospital · Bunkyo-ku, Japan
    • The Cancer Institute Hospital of JFCR · Koto-ku, Japan
    • Niigata Cancer Center Hospital · Niigata-shi, Japan
    • Osaka Prefectural Hospital Organization Osaka International Cancer Institute · Osaka-shi, Japan
    • Kanagawa Cancer Center · Yokohama-shi, Japan
    Primary completion Sep 12, 2026→Oct 30, 2025 (now actual)
    Study completion Dec 31, 2026→Oct 30, 2025 (now actual)
    Sponsor Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06542731
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Jun 1, 2021
Primary completion
Oct 30, 2025
Completion
Oct 30, 2025
Last update
Oct 20, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS-986310

Start the discussion